- Home
- ADTX
ADTX
Aditxt Inc.
as 07-26-2024 4:00pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 3.2M | IPO Year: | 2020 |
| Target Price: | $61.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -65.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $68.08 | Next Earning Date: | 08-12-2024 |
| Revenue: | $506,441 | Revenue Growth: | -46.23% |
| Revenue Growth (this year): | 95.61% | Revenue Growth (next year): | 1584.79% |
Latest Aditxt Inc. News
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Business Wire
a day ago
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
PR Newswire
3 days ago
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Business Wire
10 days ago
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
PR Newswire
a month ago
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
CNW Group
2 months ago
Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
ACCESSWIRE
2 months ago
Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
Business Insider
2 months ago
Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
Compare ADTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.